UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

British journal of cancer, 2018-10, Vol.119 (9), p.1067-1074

2018

Volltextzugriff (PDF)

Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial

The Lancet (British edition), 2010-03, Vol.375 (9717), p.816-823

2010

Volltextzugriff (PDF)

Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial

International journal of radiation oncology, biology, physics, 2015-11, Vol.93 (4), p.797-809

2015

Volltextzugriff (PDF)

An Easy Tool to Predict Survival in Patients Receiving Radiation Therapy for Painful Bone Metastases

International journal of radiation oncology, biology, physics, 2014-11, Vol.90 (4), p.739-747

2014

Volltextzugriff (PDF)

Integrase-defective lentiviral vectors: progress and applications

Gene therapy, 2010-02, Vol.17 (2), p.150-157

2010

Volltextzugriff (PDF)

Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts

Clinical cancer research, 2016-08, Vol.22 (16), p.4215-4224

2016

Volltextzugriff (PDF)

Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials

European journal of cancer (1990), 2015-09, Vol.51 (13), p.1742-1750

2015

Volltextzugriff (PDF)

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991

Journal of clinical oncology, 2016-05, Vol.34 (15), p.1748-1756

2016

Volltextzugriff (PDF)

The Curie–Da Vinci Connection: 5-Years' Experience With Laparoscopic (Robot-Assisted) Implantation for High-Dose-Rate Brachytherapy of Solitary T2 Bladder Tumors

International journal of radiation oncology, biology, physics, 2016-08, Vol.95 (5), p.1439-1442

2016

Volltextzugriff (PDF)

Quality of life of muscle-invasive bladder cancer patients after brachytherapy-based treatment: A cross-sectional study

Journal of contemporary brachytherapy, 2023-04, Vol.15 (2), p.110-116

2023

Volltextzugriff (PDF)

Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991

European journal of cancer (1990), 2009-11, Vol.45 (16), p.2825-2834

2009

Volltextzugriff (PDF)

Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial

Journal of clinical oncology, 2009-07, Vol.27 (21), p.3547-3556

2009

Volltextzugriff (PDF)

Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014)

European journal of cancer (1990), 2009-11, Vol.45 (16), p.2782-2791

2009

Volltextzugriff (PDF)

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial

Gynecologic oncology, 2018-10, Vol.151 (1), p.69-75

2018

Volltextzugriff (PDF)

Radiotherapy and Hyperthermia for Treatment of Primary Locally Advanced Cervix Cancer: Results in 378 Patients

International journal of radiation oncology, biology, physics, 2009, Vol.73 (1), p.242-250

2009

Volltextzugriff (PDF)

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer

Journal of clinical oncology, 2023-09, Vol.41 (27), p.JCO2300062-4380

2023

Volltextzugriff (PDF)

First results of triple‐modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with Stage IIB, III, and IVA cervical carcinoma

Cancer, 2005-08, Vol.104 (4), p.763-770

2005

Volltextzugriff (PDF)

Duration of Androgen Suppression in the Treatment of Prostate Cancer

The New England journal of medicine, 2009-06, Vol.360 (24), p.2516-2527

2009

Volltextzugriff (PDF)

Don't forget the bladder

Journal of contemporary brachytherapy, 2018-01, Vol.10 (2), p.178-178

2018

Volltextzugriff (PDF)

Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer

International journal of gynecological pathology, 2022-05, Vol.41 (3), p.220-226

2022

Volltextzugriff (PDF)

Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease

Journal of clinical oncology, 2021-09, Vol.39 (27), p.3022-3033

2021

Volltextzugriff (PDF)

Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials

Gynecologic oncology, 2022-09, Vol.166 (3), p.530-537

2022

Volltextzugriff (PDF)

How Small Can We Go? Partial Bladder Radiation Therapy and Brachytherapy

Seminars in radiation oncology, 2023-01, Vol.33 (1), p.76-81

2023

Volltextzugriff (PDF)

Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data

European journal of cancer (1990), 2012-07, Vol.48 (11), p.1638-1648

2012

Volltextzugriff (PDF)

1 – 25 von 352

Suche als RSS-Feed

Aktive Filter

ThemaImmunology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(296)
Mit Volltextzugriff
(268)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(189)
Life Sciences & Biomedicine
(169)
Humans
(152)
Female
(107)
Male
(70)
Adult
(67)
Middle Aged
(63)
Oncology
(56)
Aged
(47)
Biological And Medical Sciences
(37)
Animals
(33)
Medical Sciences
(28)
Radiology, Nuclear Medicine & Medical Imaging
(28)
Risk Factors
(28)
Hematology, Oncology And Palliative Medicine
(25)
Brachytherapy
(23)
Aged, 80 And Over
(21)
Medicin Och Hälsovetenskap
(21)
Genomes
(19)
Pregnancy
(19)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial

Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial

An Easy Tool to Predict Survival in Patients Receiving Radiation Therapy for Painful Bone Metastases

Integrase-defective lentiviral vectors: progress and applications

Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts

Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991

The Curie–Da Vinci Connection: 5-Years' Experience With Laparoscopic (Robot-Assisted) Implantation for High-Dose-Rate Brachytherapy of Solitary T2 Bladder Tumors

Quality of life of muscle-invasive bladder cancer patients after brachytherapy-based treatment: A cross-sectional study

Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991

Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial

Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014)

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial

Radiotherapy and Hyperthermia for Treatment of Primary Locally Advanced Cervix Cancer: Results in 378 Patients

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer

First results of triple‐modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with Stage IIB, III, and IVA cervical carcinoma

Duration of Androgen Suppression in the Treatment of Prostate Cancer

Don't forget the bladder

Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer

Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease

Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials

How Small Can We Go? Partial Bladder Radiation Therapy and Brachytherapy

Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data

Aktive Filter

Suchergebnisse filtern